|
By Dross at 2007-06-05 22:14
|
|
- Results of the randomized phase III EORTC 40983 Intergroup study, or EPOC study, demonstrate for the first time that peri-operative (pre and post surgery) FOLFOX4 (Eloxatinterm(R) (oxaliplatintermterm injection) in combination with a standard chemotherapyterm regimen for colon cancer, 5-fluorouraciltermtermtermterm/leucovorintermterm (5-FUterm/LV)) given to patients with resectable liver metastases from colorectal cancer significantly improved Progression-Free Survival (PFS) compared to surgery alone. (PFS is the time from the start of therapy until disease progression or death). The EPOC study results were presented today at the Plenary Session of the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.
|
|
read more | 1538 reads
|
|
By HCat at 2007-01-16 12:35
|
|
Colorectal Cancer Basics
Hereditary CRC
Colorectal cancer (CRC) can be divided into two basic types, hereditary or sporadic.
   Hereditary CRC are germlineterm (passed to offspring) mutations (a damaging change in DNA) with two well described forms. These hereditary mutations are thought to reduce the time it takes for the cells to turn cancerous. Mutations can be thought of in terms of “hitsâ€. One hit is one mutation. It is thought that a normal cell needs 3 to 6 hits to become cancerous. With an inherited mutation, there is one fewer hit needed to reach the correct number to transform the cell to cancer. One odd aspect to CRC is that there is a relatively well defined set of events for the progression from adenomaterm to carcinomaterm.
|
|
read more | 22562 reads
|
Register
